BioSpace News Archive

Johnson & Johnson announced updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer with select FGFR alterations.

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest real-world patient cohort review of JELMYTO for pyelocalyceal solution presented at the American Urological Association Meeting 2024 in San Antonio, TX.

GE HealthCare unveiled SIGNA MAGNUS, an FDA 510 pending head-only magnetic resonance scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems.